As the NANOG/HDAC1 axis has been implicated as a central channel in the development of resistance to CTL-based immunotherapies, we believe that HDAC1 inhibition may be an effective strategy to control ICB therapy–refractory tumor cells with elevated expression of NANOG. Here, HDAC1 is linked to neoplasm.